Neuroendocrine breast cancer is a rare type of breast cancer in which the cancer cells show neuroendocrine features — traits shared with the hormone-releasing cells found in the nervous system and the digestive tract. It is still a breast cancer: it begins in the breast and is usually found the same way as other types. But those unusual cell features affect how it is classified, and how a specialist team plans treatment. It is uncommon, and individual cases differ a great deal, especially in how the cells look and behave under the microscope.
Key Takeaways
- Neuroendocrine breast cancer starts in the breast, but its cells show features of neuroendocrine cells — the hormone-releasing cells found elsewhere in the body.
- It is rare; current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov).
- It most often appears as a lump, like other breast cancers, and only a biopsy with pathology tests can identify the type.
- Pathologists describe it by how the cells look — from slower-growing, well-differentiated tumours to faster-growing, poorly differentiated carcinomas — and that distinction shapes the plan.
- Treatment is planned by a specialist team around the tumour’s features, its stage, and your overall health.
- Your own pathology report holds the details that matter — general information like this article cannot describe your case.
What “Neuroendocrine” Means
Neuroendocrine cells are a normal part of the body. They sit in many organs — the gut, the lungs, the pancreas, and in small numbers in the breast — and their job is to receive signals and release hormones in response. A cancer is called neuroendocrine when its cells take on the appearance and behaviour of these cells. Pathologists recognise the pattern under the microscope and confirm it with special stains that detect marker proteins these cells typically carry.
In the breast, that produces an unusual situation: a cancer growing in breast tissue, found and staged like a breast cancer, whose cells carry the signature of a different cell family. Our pillar guide, Types of Breast Cancer Compared, shows where a type like this one sits alongside the far more common ductal and lobular cancers. The word “neuroendocrine” in your report is describing the cells’ features — it is not saying the cancer came from the nervous system, and it does not mean the cancer started somewhere else and spread to the breast. Distinguishing a cancer that truly began in the breast from one that spread there from another site is one of the first things the pathology team works out, because it changes the picture.
How It Differs From Other Breast Cancers
The most important difference is inside the tumour itself. Neuroendocrine breast cancers are described along a spectrum based on how the cells look and how quickly they appear to grow. At one end are well-differentiated tumours, whose cells still resemble normal neuroendocrine cells and tend to grow more slowly. At the other end are poorly differentiated neuroendocrine carcinomas, whose cells look very abnormal and tend to grow faster. Two cancers can share the “neuroendocrine” label and behave quite differently, which is why the exact wording of a pathology report matters so much.
| Feature | Neuroendocrine breast cancer | Most breast cancers |
|---|---|---|
| What the cells show | Features of neuroendocrine (hormone-releasing) cells, confirmed by special marker stains | Features of the duct or lobule cells they started from |
| How it is grouped | By how the cells look — well-differentiated tumours through to poorly differentiated carcinomas | By where it started (ductal, lobular) and by hormone receptor and HER2 results |
| What drives planning | The cell appearance and grade, the stage, hormone receptor results, and overall health | Stage, hormone receptor and HER2 results, grade, and overall health |
| How common it is | Rare — one of the uncommon types | The ductal and lobular types account for most diagnoses |
It belongs to a small family of rare breast types, each unusual in its own way. Metaplastic breast cancer involves cells that have changed into other tissue types; secretory breast carcinoma is defined by a particular gene change; adenoid cystic carcinoma shares its name with a salivary gland cancer. Neuroendocrine breast cancer’s defining trait is the hormone-cell signature its cells carry. Many of these tumours also test positive for hormone receptors, which is one of the results your team weighs when planning.
How It May Appear
Neuroendocrine breast cancer most often appears the way other breast cancers do: as a lump in the breast, sometimes found by the person themselves and sometimes picked up on a screening mammogram. There is nothing about how a lump feels that marks it out as neuroendocrine — the type only becomes known once tissue is examined in the laboratory. Occasionally, a tumour that produces hormones can cause symptoms elsewhere in the body, but that is uncommon, and most people have no such signs.
The practical point is the familiar one: most breast lumps are not cancer, and among those that are, the common types are far more likely than this one. A new lump or a persistent change deserves a prompt appointment whatever it turns out to be, because the feel of a lump cannot settle what it is.
How It Is Diagnosed
The first steps are the standard ones: a clinical examination, imaging such as a mammogram or ultrasound to map the area, and a biopsy, in which a small sample is taken for the laboratory. In the laboratory, the pathologist looks at the cell pattern and runs the special marker stains that confirm whether neuroendocrine features are present. The report will also describe how differentiated the cells are — the distinction between a well-differentiated tumour and a poorly differentiated carcinoma — and the tumour’s grade, stage work-up, and hormone receptor and HER2 results.
Because this type is uncommon, the team may also check carefully that the cancer began in the breast rather than spreading there from a neuroendocrine tumour elsewhere, since neuroendocrine cancers can arise in organs such as the digestive tract and lungs. Scans may be part of that picture. It is also common for uncommon types to be reviewed by pathologists with particular experience in them, and for the case to be discussed by a wider specialist team. Asking who has reviewed your pathology, and what the exact wording of the report says, is always reasonable.
How Treatment Is Generally Planned
Treatment is planned around the individual tumour, using the same broad tools as for other breast cancers — surgery, radiation therapy, and drug treatments — weighted by this type’s particular features. How the cells look matters a great deal: a slower-growing, well-differentiated tumour and a fast-growing, poorly differentiated carcinoma are not approached in the same way, and the hormone receptor results, the stage, and your overall health all feed into the decision. Precisely because these tumours are uncommon, there is no single standard recipe this article could describe, and it names no drugs or schedules on purpose.
What you can expect is a plan explained in terms of your own report: what kind of neuroendocrine tumour it is, how far it extends, and what each part of treatment is intended to do. If your team suggests seeking input from a centre with more experience of rare breast types, that is a normal step for an uncommon diagnosis, not a warning sign. General background on rare breast cancers is published by the American Cancer Society at cancer.org and the National Cancer Institute at cancer.gov. Individual cases differ — sometimes a great deal — and your own doctor and care team are the authority on yours.
Questions to Ask Your Doctor
- What exactly does my pathology report say — is it described as a well-differentiated tumour or a poorly differentiated carcinoma?
- Did the laboratory confirm the cancer started in the breast, rather than spreading from somewhere else?
- What were the hormone receptor and HER2 results, and how do they affect my plan?
- What stage is the cancer, and which scans were used to decide that?
- Will a specialist in rare breast cancers review my case or help plan my treatment?
- In general terms, what will my treatment involve, and what is each part intended to do?
- What follow-up will I have after treatment ends?
Frequently Asked Questions
Is neuroendocrine breast cancer the same as a neuroendocrine tumour elsewhere in the body?
They share a cell type, but they are not the same situation. A neuroendocrine cancer that begins in the breast is diagnosed and planned for as a breast cancer with neuroendocrine features, while neuroendocrine tumours of the gut or lungs are handled within their own systems. Part of the diagnostic work is confirming which situation you are in.
Does “neuroendocrine” mean the cancer came from my nerves?
No. The name describes cells that both receive signals, like nerve cells, and release hormones. These cells exist normally in many organs, including the breast. It does not mean the cancer started in the nervous system.
Why does it matter whether the cells are well or poorly differentiated?
Because it is one of the strongest clues to how the tumour is likely to behave. Well-differentiated tumours tend to grow more slowly; poorly differentiated carcinomas tend to grow faster and are planned for differently. Your team’s recommendations follow from that distinction together with the stage and other results.
Is this type more serious than other breast cancers?
There is no single answer — the picture ranges widely with this type, from slower-growing tumours to faster-growing carcinomas. What matters is your own combination of cell appearance, stage, and other results, which your care team can explain in your case.
Where can I find reliable figures about this type?
Because it is uncommon, published figures are limited and can change as research develops. Current general information is published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov), and your care team can explain what applies to you.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- Metaplastic Breast Cancer Explained
- Secretory Breast Carcinoma Explained
- Adenoid Cystic Carcinoma of the Breast Explained
- Apocrine Breast Cancer Explained
- Breast Angiosarcoma Explained: A Rare Cancer of Blood Vessels
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.